Naoto Oku Selected Research

Liposomes (Liposome)

2/2022	Application and Utility of Liposomal Neuroprotective Agents and Biomimetic Nanoparticles for the Treatment of Ischemic Stroke.
10/2021	New strategy for MS treatment with autoantigen-modified liposomes and their therapeutic effect.
10/2020	Release rate is a key variable affecting the therapeutic effectiveness of liposomal fasudil for the treatment of cerebral ischemia/reperfusion injury.
10/2020	Development of tissue factor-targeted liposomes for effective drug delivery to stroma-rich tumors.
12/2019	Suppression of Cerebral Ischemia/Reperfusion Injury by Efficient Release of Encapsulated Ifenprodil From Liposomes Under Weakly Acidic pH Conditions.
1/2019	Design of a Novel PEGylated Liposomal Vector for Systemic Delivery of siRNA to Solid Tumors.
1/2019	Macrophage-targeted, enzyme-triggered fluorescence switch-on system for detection of embolism-vulnerable atherosclerotic plaques.
1/2018	Co-administration of liposomal fasudil and tissue plasminogen activator ameliorated ischemic brain damage in occlusion model rats prepared by photochemically induced thrombosis.
1/2018	Involvement of Tumor Lymphatic System in Translocation of Intratumorally Injected Liposomes.
5/2017	Targeted delivery of anticancer drugs to tumor vessels by use of liposomes modified with a peptide identified by phage biopanning with human endothelial progenitor cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naoto Oku Research Topics

Disease

81	Neoplasms (Cancer) 10/2020 - 01/2002
17	Neoplasm Metastasis (Metastasis) 02/2021 - 01/2002
12	Brain Ischemia (Cerebral Ischemia) 02/2022 - 05/2012
11	Seizures (Absence Seizure) 01/2013 - 09/2002
10	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 12/2019 - 05/2012
10	Melanoma (Melanoma, Malignant) 01/2015 - 03/2008
9	Reperfusion Injury 02/2022 - 02/2009
9	Ischemia 01/2018 - 02/2009
8	Ischemic Stroke 02/2022 - 11/2015
8	Carcinoma (Carcinomatosis) 01/2018 - 06/2002
7	Sarcoma (Soft Tissue Sarcoma) 01/2018 - 04/2003
7	Fibrosarcoma 02/2014 - 02/2005
6	Stroke (Strokes) 05/2017 - 05/2012
4	Tetanus 01/2012 - 04/2010
4	Phototoxic Dermatitis (Phototoxicity) 11/2008 - 07/2003
3	Inflammation (Inflammations) 02/2021 - 04/2014
3	Breast Neoplasms (Breast Cancer) 02/2021 - 06/2012
3	Dementia (Dementias) 01/2018 - 02/2008
3	Glioma (Gliomas) 01/2011 - 05/2002
3	Brain Neoplasms (Brain Tumor) 01/2011 - 05/2002
3	Epilepsy (Aura) 04/2004 - 09/2002
2	Hyperglycemia 01/2021 - 01/2019
2	Hemolysis 01/2021 - 07/2020
2	Sepsis (Septicemia) 01/2021 - 12/2017
2	Cerebral Hemorrhage 01/2019 - 01/2017
2	Thrombosis (Thrombus) 01/2018 - 01/2017
2	Alzheimer Disease (Alzheimer's Disease) 01/2018 - 02/2008
2	Necrosis 01/2017 - 11/2008
2	Choroidal Neovascularization 01/2013 - 03/2011

Drug/Important Bio-Agent (IBA)

61	Liposomes (Liposome)IBA 02/2022 - 01/2002
23	Peptides (Polypeptides)IBA 10/2021 - 01/2002
21	Pharmaceutical PreparationsIBA 02/2022 - 03/2004
16	ZincIBA 01/2013 - 05/2002
14	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2021 - 04/2002
14	Small Interfering RNA (siRNA)IBA 07/2020 - 03/2007
12	Neuroprotective AgentsIBA 02/2022 - 05/2012
12	alanyl-prolyl-arginyl-prolyl-glycineIBA 01/2016 - 04/2002
11	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2009 - 04/2003
10	Photosensitizing Agents (Photosensitizers)IBA 01/2009 - 01/2002
9	Proteins (Proteins, Gene)FDA Link 10/2019 - 05/2007
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2019 - 11/2004
9	Kainic Acid (Kainate)IBA 01/2009 - 05/2003
8	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2018 - 03/2004
8	Triethylenephosphoramide (TEPA)IBA 01/2016 - 01/2011
7	Verteporfin (Visudyne)FDA Link 01/2009 - 04/2003
5	PolymersIBA 01/2021 - 03/2010
5	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 12/2019 - 04/2010
5	Tacrolimus (Prograf)FDA LinkGeneric 05/2017 - 04/2013
5	Drug CarriersIBA 01/2017 - 11/2004
5	Matrix Metalloproteinases (MMPs)IBA 01/2017 - 09/2003
5	Therapeutic UsesIBA 01/2016 - 02/2005
5	CholesterolIBA 01/2013 - 03/2004
4	fasudil (AT 877)IBA 10/2020 - 06/2016
4	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2019 - 11/2015
4	Matrix Metalloproteinase 14 (MT1-MMP)IBA 05/2007 - 09/2003
3	SolutionsIBA 02/2022 - 05/2002
3	Heparin-binding EGF-like Growth Factor (HB-EGF)IBA 01/2018 - 06/2012
3	nobiletinIBA 01/2018 - 01/2014
3	Epidermal Growth Factor (EGF)IBA 01/2018 - 06/2012
3	Peptide LibraryIBA 05/2017 - 06/2002
3	LuciferasesIBA 02/2014 - 03/2011
3	arginyl-glycyl-aspartic acidIBA 01/2013 - 01/2005
3	1,2-distearoylphosphatidylethanolamine (DSPE)IBA 06/2012 - 02/2004
3	TeaIBA 01/2011 - 09/2003
3	OligopeptidesIBA 01/2010 - 01/2005
3	Oxygen (Dioxygen)IBA 02/2009 - 05/2004
3	dpp-cndacIBA 05/2008 - 06/2002
3	EpitopesIBA 05/2007 - 01/2002
3	Glutamic Acid (Glutamate)FDA Link 08/2005 - 05/2003
2	Indicators and Reagents (Reagents)IBA 02/2021 - 10/2019
2	HydrogelsIBA 01/2021 - 10/2019
2	Histones (Histone)IBA 01/2021 - 12/2017
2	Radioisotopes (Radionuclides)IBA 01/2018 - 05/2002
2	Lipid NanoparticlesIBA 01/2018 - 07/2014
2	Antineoplastic Agents (Antineoplastics)IBA 05/2017 - 01/2005
2	InterferonsIBA 01/2017 - 01/2016
2	Messenger RNA (mRNA)IBA 01/2017 - 03/2007
2	tetraethylenepentamineIBA 01/2016 - 01/2013
2	sepantroniumIBA 01/2015 - 09/2014
2	TOR Serine-Threonine KinasesIBA 01/2015 - 01/2011
2	Heparin (Liquaemin)FDA LinkGeneric 07/2014 - 06/2012
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 07/2014 - 06/2012
2	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2013 - 01/2011
2	LigandsIBA 01/2013 - 10/2006
2	Angiogenesis InhibitorsIBA 01/2013 - 03/2011
2	MicroRNAs (MicroRNA)IBA 01/2013 - 08/2011
2	Erythropoietin FDA Link 12/2012 - 05/2012
2	rhinacanthin-NIBA 01/2012 - 11/2006
2	2-Amino-5-phosphonovalerate (2 Amino 5 phosphonovalerate)IBA 01/2012 - 04/2010
2	EstersIBA 01/2012 - 10/2006
2	NaphthoquinonesIBA 01/2012 - 10/2006

Therapy/Procedure

32	Therapeutics 01/2021 - 01/2002
10	Drug Therapy (Chemotherapy) 01/2018 - 04/2002
9	Intravenous Injections 01/2019 - 05/2002
9	Photochemotherapy (Photodynamic Therapy) 01/2009 - 01/2002
7	Lasers (Laser) 01/2009 - 03/2004
3	Thrombolytic Therapy 01/2019 - 11/2015
3	Injections 01/2015 - 04/2005
2	Intravenous Administration 06/2016 - 04/2013
2	Intravitreal Injections 01/2013 - 03/2011